---
title: "Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD"
date: "2025-02-08 01:17:56"
summary: "Zerbor  Coya Therapeutics, Inc. (NASDAQ:COYA) is a US biotech working on neurodegenerative and autoimmune using T cell [Treg] modulation. Their main candidates are COYA 302 and COYA 301. COYA 302 is probably the most promising today, and it’s intended for multiple indications"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518273792/image_518273792.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Tablet with the text ALS on the display](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518273792/image_518273792.jpg?io=getty-c-w750) 



Zerbor





**Coya Therapeutics, Inc.** (NASDAQ:[COYA](https://seekingalpha.com/symbol/COYA "Coya Therapeutics, Inc.")) is a US biotech working on neurodegenerative and autoimmune using T cell [Treg] modulation. Their main candidates are COYA 302 and COYA 301. COYA 302 is probably the most promising today, and it’s intended for multiple indications

[seekalpha_articles](https://seekingalpha.com/article/4756246-coya-therapeutics-now-pivots-toward-phase-2-in-als-and-ftd)
